Boston’s life-sciences heavyweights are banding together around a big idea: take one-off genetic rescues for rare diseases and turn them into something that looks more like standard medical care. This week, local research leaders unveiled a new nonprofit, the Center for Therapeutic Genetics, that aims to pool design tools, disease models, manufacturing processes and clinical protocols so personalized gene medicines can be built faster and at lower cost. The effort will first zero in on precision gene-editing treatments for children with rare genetic epilepsies while it works up an operational playbook that could be reused for other conditions.
According to Broad Institute, the center is set up as a nonprofit collaboration between the Broad, Boston Children’s Hospital and The Jackson Laboratory, with a mission to create and openly share precision medicines, methods, data and training so other clinicians can replicate treatments. The Broad named Winston Yan as founding director, and Yan called “scaling and sustaining treatment for ultra-rare disease” a hard problem, part of the logic for building a shared platform. The announcement also names co-founders David Liu, Wendy Chung and Timothy Yu, and casts CTG as an attempt to make individualized genetic medicines “faster, safer, less expensive, and more accessible.”
Patient advocates and clinicians welcomed the launch as a meaningful step, while warning that speed and access will be real tests. Pamela Gavin, chief executive officer of the National Organization for Rare Disorders, told The Boston Globe the center could meet a “phenomenal need” if it succeeds at building scalable approaches to genetic medicine. Those needs are stark: the National Organization for Rare Disorders estimates that about one in 10 Americans has a rare disease, roughly half are children, and fewer than 5 percent of known rare conditions have an FDA-approved treatment.
Federal Backing And The ARPA-H Push
Federal agencies are already betting on this model of made-to-order gene-editing. Earlier this month, ARPA-H rolled out its THRIVE initiative, which will put up to $160 million into teams working on custom gene-editing treatments, according to STAT. A Broad-led consortium focused on pediatric epilepsies, the PERC project, was picked for an ARPA-H award of up to $34.5 million, with The Jackson Laboratory named as a lead partner in that work, per The Jackson Laboratory. CTG leaders say that money will fuel preclinical studies, brain-directed delivery technology and the regulatory evidence needed to move toward first-in-human trials.
How The Center Plans To Scale Treatments
CTG’s founders describe a platform strategy rather than a single-product play. Design tools, disease models, safety data, manufacturing processes and clinical protocols created for one program are intended to be reused across others, cutting development time and cost, according to Broad Institute. The center also says it plans to work with regulators to build evidence and standards that could let individualized genetic treatments function more like established clinical procedures. The shared playbook is meant to help other hospitals and academic centers reproduce programs without each team rebuilding every step from scratch.
What Families Should Know
For now, CTG is still in its founding phase and is not accepting patient referrals or providing clinical care, officials told The Boston Globe, and leaders caution families not to expect immediate enrollment. Timothy Yu, one of CTG’s founding partners at Boston Children’s, said the center plans to lean on philanthropic support instead of asking families to bankroll individual programs, and that it will prioritize conditions that move the field forward most quickly and reliably. Organizers say they will publish program timelines and clinical-trial openings as projects move from pilot work toward patient care.
Families and researchers can track CTG’s progress and partner announcements on the center’s website, Center for Therapeutic Genetics, where founders say they will share updates on research programs, collaborations and, eventually, clinical opportunities. Scientists involved acknowledge that the path from early-stage science to routine clinical use is a long one, but argue that a shared, open platform could make precision genetic medicines meaningfully more scalable for families who need them.
